Dr. Tam Discusses BTK Inhibition in CLL

Dr. Tam Discusses BTK Inhibition in CLL

Next-Generation BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - Dr. Constantine Tam ASH 2021Подробнее

Next-Generation BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - Dr. Constantine Tam ASH 2021

Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine TamПодробнее

Zanubrutinib Combined with Venetoclax for CLL Patients with Deletion 17p - Dr. Constantine Tam

Part 2 - How do I use BTKi for CLL management? - Dr. Nitin Jain, USAПодробнее

Part 2 - How do I use BTKi for CLL management? - Dr. Nitin Jain, USA

Dr. Goy Discusses BTK Inhibitors in MCLПодробнее

Dr. Goy Discusses BTK Inhibitors in MCL

Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?Подробнее

Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?

The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary resultsПодробнее

The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results

Dr. Tam on BTK Inhibitor BGB-3111 in CLLПодробнее

Dr. Tam on BTK Inhibitor BGB-3111 in CLL

Dr. Tam Discusses the DUO Trial for CLLПодробнее

Dr. Tam Discusses the DUO Trial for CLL

Dr. Furman on Second-Generation BTK Inhibitors in CLLПодробнее

Dr. Furman on Second-Generation BTK Inhibitors in CLL